Twist Bioscience, led by CEO Emily Leproust, is enjoying a stock lift after announcing increased ... [+] revenues and settlement of a trade secret lawsuit filed by Agilent Technologies. Investors may feel more confident in Twist’s prospects in silicon-based DNA manufacturing - a big component of the synthetic biology industry. SynBioBetaOne of the biggest synthetic biology companies is enjoying a stock lift on settling a nagging trade secrets lawsuit. Twist Bioscience, a synthetic DNA manufacturer serving a wide range of industries, has announced reaching a settlement agreement regarding a trade secret lawsuit filed by Agilent Technologies in 2016. On Thursday morning, shares of Twist Bioscience (NASDAQ: TWST) were trading at just below $27.

Source: Forbes February 08, 2020 00:11 UTC